Meet Luke
Luke co-founded MPM Capital, the predecessor to MPM BioImpact, in 1997 and co-led the firm for twenty-five years. During that period, MPM invested in more than 100 companies, and those companies advanced more than fifty therapeutics through regulatory approval. Luke has served on more than thirty boards, including nine public companies.
Over the past decade, Luke has been a co-founder of seven companies. He was co-founder and Chair of Co-Stim, a pioneering immuno-oncology company acquired by Novartis. He was also co-founder and Chair of Maverick, an immuno-oncology company acquired by Takeda.
Luke stepped down from his full-time role at MPM in 2023 to devote additional focus to his multi-decade involvement with the Scleroderma Research Foundation. He has chaired the board of the Scleroderma Research Foundation since 2002 and has co-led its research over that period.
